REG - ValiRx PLC - Result of GM, Issue of Equity
04/01/2024 14:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240104:nRSD6992Ya&default-theme=true
RNS Number : 6992Y ValiRx PLC 04 January 2024
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO
CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER ARTICLE 7 OF THE MARKET
ABUSE REGULATION (EU) 596/2014 AS AMENDED BY REGULATION 11 OF THE MARKET ABUSE
(AMENDMENT) (EU EXIT) REGULATIONS 2019/310. UPON THE PUBLICATION OF THIS
ANNOUNCEMENT VIA REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS
NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
4 January 2024
VALIRX PLC
("ValiRx" or the "Company")
Result of General Meeting
Issue of Equity and Total Voting Rights
Director and PDMR Shareholding
ValiRx plc (the "Company") (AIM: VAL), announces that, further to the
Conditional Fundraise & Notice of General Meeting announcement dated 13
December 2023, at its General Meeting held earlier today, resolutions 1 and 3
were duly passed and resolution 2 was not passed. Details of the votes
received in respect of the resolutions will be available shortly on the
Company's website.
Director and PDMR Shareholdings
Following completion of the Fundraising, the shareholdings of the Directors
and PDMRs who participated in the Fundraising are set out in the table below:
Director/PDMR Existing beneficial shareholding Fundraising Shares subscribed for Beneficial shareholding on completion of the Fundraising Beneficial shareholding as a percentage of the Enlarged Share Capital
Suzanne Dilly 416,668 66,666 483,334 0.37%
Kevin Cox 372,333 150,000 522,333 0.39%
Gerry Desler 128,668 66,666 195,334 0.15%
Martin Lampshire 144,000 150,000 294,000 0.22%
Stella Panu - 333,333 333,333 0.25%
Cathy Tralau-Stewart - 66,666 66,666 0.05%
Issue of Equity
The Placing Shares, the Subscription Shares and the Retail Offer Shares have
been allotted, conditional upon Admission, and application has been made to
the London Stock Exchange for, in aggregate, 30,029,063 Placing Shares,
Subscription Shares and Retail Offer Shares to be admitted to trading on AIM.
Admission is expected to occur at 8.00 a.m. on 8 January 2024, with dealings
in the Placing Shares, the Subscription Shares and the Retail Offer Shares
commencing at the same time. The Placing Shares, the Subscription Shares and
the Retail Offer Shares will rank pari passu with all other issued Shares.
The Fundraising remains conditional, inter alia, upon Admission and the
Placing Agreement not being terminated in accordance with its terms.
Total Voting Rights
For the purpose of the Disclosure Guidance and Transparency Rules, following
Admission the enlarged issued share capital of the Company will comprise
132,348,673 ordinary shares of 0.1 pence each. The Company does not hold any
shares in the treasury. The above figure may be used by shareholders as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
Company, under the Disclosure Guidance and Transparency Rules.
Capitalised terms used in this announcement have the meaning given to them in
the Conditional Fundraise, Notice of General Meeting announcement dated 13
December 2023, unless otherwise defined in this announcement.
The Directors of the Company take responsibility for this announcement.
For more information, please contact:
ValiRx plc Tel: +44 (0) 2476 796496
www.valirx.com (http://www.valirx.com)
Dr Suzanne Dilly, CEO Suzanne.Dilly@valirx.com (mailto:Suzanne.Dilly@valirx.com)
V Formation (Public Relations) +44 (0) 115 787 0206
www.vformation.biz (http://www.vformation.biz)
Lucy Wharton - Senior PR Executive
Sue Carr - Director lucy@vformation.biz
sue@vformation.biz
Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0) 20 7213 0880
Liam Murray/Jo Turner/Ludovico Lazzaretti
Cavendish Capital Markets Limited (Joint Broker) Tel: +44 (0) 20 7397 8900
Dale Bellis/Michael Johnson (Sales)
Callum Davidson/Giles Balleny (Corporate Finance)
Turner Pope Investments (Joint Broker) Tel: +44 (0) 20 3657 0050
James Pope / Andy Thacker
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name a) Suzanne Dilly
b) Kevin Cox
c) Gerry Desler
d) Martin Lampshire
e) Stella Panu
f) Cathy Tralau-Stewart
2 Reason for notification
a. Position/Status a) Director
b) Director
c) Director
d) Director
e) Director
f) PDMR
b. Initial notification/ Initial notification
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name ValiRx PLC
b. LEI 213800VQKB9SJCQDET40
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Ordinary Shares
Identification Code
ISIN: GB00BLH13C52
b. Nature of the transaction Purchase of shares as part of the Fundraising
c. Price(s) and volume(s)
Price(s) Volume(s)
a) 6p a) 66,666
b) 6p b) 150,000
c) 6p c) 66,666
d) 6p d) 150,000
e) 6p e) 333,333
f) 6p f) 66,666
d. Aggregated information
- Aggregated Volume N/A
- Price
e. Date of the transaction a) 04/01/2024
b) 04/01/2024
c) 04/01/2024
d) 04/01/2024
e) 04/01/2024
f) 04/01/2024
f. Place of the transaction Outside a trading venue
2
Reason for notification
a.
Position/Status
a) Director
b) Director
c) Director
d) Director
e) Director
f) PDMR
b.
Initial notification/
Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a.
Name
ValiRx PLC
b.
LEI
213800VQKB9SJCQDET40
4
Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a.
Description of the financial instrument, type of instrument
Identification Code
Ordinary Shares
ISIN: GB00BLH13C52
b.
Nature of the transaction
Purchase of shares as part of the Fundraising
c.
Price(s) and volume(s)
Price(s)
Volume(s)
a) 6p
b) 6p
c) 6p
d) 6p
e) 6p
f) 6p
a) 66,666
b) 150,000
c) 66,666
d) 150,000
e) 333,333
f) 66,666
d.
Aggregated information
- Aggregated Volume
- Price
N/A
e.
Date of the transaction
a) 04/01/2024
b) 04/01/2024
c) 04/01/2024
d) 04/01/2024
e) 04/01/2024
f) 04/01/2024
f.
Place of the transaction
Outside a trading venue
Notes for Editors
About ValiRx
ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.
ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.
Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.
ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.
Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.
ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.
For further information, visit: www.valirx.com (http://www.valirx.com)
Cautionary statement
Certain statements made in this announcement are forward-looking statements.
Such statements are based on current expectations and assumptions and are
subject to a number of risks and uncertainties that could cause actual events
or results to differ materially from any expected future events or results
expressed or implied in these forward-looking statements. Persons receiving
this announcement should not place undue reliance on forward-looking
statements. Unless otherwise required by applicable law, regulation or
accounting standard, the Company does not undertake to update or revise any
forward-looking statements, whether as a result of new information, future
developments or otherwise.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END ROMEADFLELSLEFARecent news on ValiRx
See all newsREG - ValiRx PLC - Directorate Changes
AnnouncementREG - ValiRx PLC - Evaluation Agreement with Imperial College London
AnnouncementREG - ValiRx PLC - Board Re-structuring and update on requisition
AnnouncementREG - ValiRx PLC - Shareholder Requisition Notice
AnnouncementREG - ValiRx PLC - Proposed Appointment of Non-Executive Director
Announcement